RadNet, Inc. — Q1 2023 Form 10-Q
Business context and reporting period
For the three months ended March 31, 2023, RadNet operated 363 outpatient imaging centers, directly or through joint ventures, across seven U.S. states, and reported Imaging Centers and Artificial Intelligence (AI) segments. It also develops imaging software and AI tools. Financial statements are unaudited; amounts below are USD unless stated otherwise.
Financial and operating results
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Total service revenue | $390.6 million | $341.8 million |
| Operating income (loss) | $6.7 million | $(1.7) million |
| Net income (loss) attributable to RadNet common stockholders | $(21.0) million | $3.0 million |
| Diluted earnings (loss) per share | $(0.36) | $0.05 |
| Cash from operating activities | $32.6 million | $0.9 million |
| Cash used in investing activities | $65.6 million | $61.6 million |
- Revenue increased 14.3%. Service-fee revenue rose to $352.4 million from $303.3 million, while capitation revenue was $38.1 million versus $38.5 million.
- Operating margin was 1.7%, compared with negative 0.5%. Cost of operations, excluding depreciation and amortization, was $351.9 million, or 90.1% of revenue, versus $315.0 million, or 92.2%.
- Interest expense rose 35.5% to $15.7 million. The reported income-tax line was a $1.1 million benefit in Q1 2023, versus a $1.5 million benefit in Q1 2022.
- Adjusted EBITDA, a non-GAAP measure, was $48.2 million including AI-segment losses and $52.7 million excluding those losses. The corresponding 2022 figures were $38.1 million and $41.7 million.
- Cash and cash equivalents were $90.8 million at March 31, down from $127.8 million at year-end 2022. Accounts receivable was $176.4 million. Working capital excluding current operating lease liabilities was negative $5.9 million.
- Total debt obligations were $868.3 million, including $852.4 million long-term debt net of discounts and current portion. The company had no borrowings on either revolving facility; $187.4 million was available under Barclays and $50.0 million under Truist. It reported compliance with all credit covenants.
- Capital expenditures were $55.9 million; acquisitions used $9.6 million. Cash declined by $37.0 million during the quarter.
Material changes versus the prior comparable period
- Imaging Center revenue increased 13.9% to $388.4 million; same-center revenue rose 7.2%. Same-center procedure volume increased 8.4%, with advanced imaging procedures up 10.3%. Management separately reported overall procedure-volume growth of 14%.
- AI revenue increased to $2.1 million from $0.6 million, while AI segment operating loss widened to $6.9 million from $5.6 million. The segment’s net loss was $7.6 million versus $4.4 million.
- Parent-company net results shifted from income to loss. A major factor was the non-cash interest-rate-hedge fair-value change: a $4.1 million loss in Q1 2023 versus a $20.8 million gain in Q1 2022. Higher interest expense also reduced earnings.
- Operating cash flow improved from $0.9 million to $32.6 million; the filing notes that the prior-year cash-flow comparison was affected by the non-cash hedge fair-value change.
- RadNet completed four imaging-related acquisitions for total consideration of approximately $9.9 million, primarily to strengthen California and New York operations.
Outlook, commentary, risks and unusual items
- Management said existing capital resources, expected operating cash flow and available revolver capacity should be sufficient for operations for at least the next 12 months. No specific numerical revenue or earnings guidance is provided in the filing text.
- Management cited strong procedure-volume growth, new center openings and the February launch of Enhanced Breast Cancer Detection, powered by DeepHealth AI, in initial Florida, New Jersey and New York locations. It expects AI growth over time through product commercialization and expansion of cancer-detection programs.
- RadNet operates in a capital-intensive business and expects effective rates and interest expense on senior credit facilities to continue rising in the near term. At quarter-end, $712.3 million of First Lien Term Loans and $148.1 million of Truist term debt were outstanding. The First Lien facility transitioned from LIBOR to SOFR effective March 31, 2023.
- Interest-rate sensitivity disclosures estimate that a 1% rate increase would add approximately $2.1 million in annual interest expense on First Lien debt and $1.5 million on Truist debt. Existing swaps have $500 million aggregate notional; portions are no longer effective as cash-flow hedges, so fair-value changes are recognized in earnings.
- Other stated risks include reimbursement and payor-contract changes, labor and other inflation, acquisition integration and funding needs, and the ability to maintain covenant compliance or obtain financing. The company reported no material expected adverse effect from pending legal matters but noted outcomes are uncertain. It has no foreign-exchange contracts to mitigate exposure from international operations.
- Contingent acquisition consideration was measured using significant unobservable inputs; reported amounts included $11.3 million for Aidence, $4.4 million for Quantib and $13.1 million for Heart and Lung Imaging.
Important facts for investors to verify
- Whether procedure-volume growth, same-center revenue trends and reimbursement rates remain durable, and how acquisition contributions affect reported growth.
- Whether rising interest costs and hedge accounting volatility continue to pressure GAAP earnings, and the company’s exposure under its variable-rate debt.
- Whether operating cash flow can support substantial capital spending, acquisitions and debt service while cash balances are lower.
- Progress toward commercializing AI products, including revenue growth relative to continuing segment losses.
- Future outcomes and valuation changes for acquisition contingencies, and the assumptions supporting management’s 12-month liquidity outlook.